Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.46 |
| ▸ | BRAF | P15056 | 13/20 | 0.43 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366948 | 0.90 | KDR (0.48) | KDRBRAFKITRAF1 | |
| SCHEMBL6480092 | 0.90 | RAF1 (0.47) | KDRBRAFKITRAF1 | |
| SCHEMBL3366914 | 0.89 | KDR (0.56) | KDRBRAFKITRAF1 | |
| SCHEMBL13363759 | 0.89 | KDR (0.53) | KDRBRAFKITRAF1 | |
| SCHEMBL13363778 | 0.89 | KDR (0.47) | KDRBRAFKITRAF1 | |
| SCHEMBL13799389 | 0.88 | KDR (0.46) | KDRBRAFKITRAF1 | |
| SCHEMBL13790462 | 0.87 | KDR (0.56) | KDRBRAFKITRAF1 | |
| SCHEMBL13363801 | 0.87 | KDR (0.45) | KDRBRAFKIT | |
| SCHEMBL3366820 | 0.86 | KDR (0.44) | KDRBRAFKITKIF11 | |
| SCHEMBL13363772 | 0.86 | KDR (0.44) | KDRBRAFKITRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4658037-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | claimed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | claimed |
| JP-2006519264-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | disclosed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | VHL, HCCS, CDK4 | KDR 145/4885BRAF 419/4885KIT 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.